Opinion: The Potential Role of Amyloid Beta Peptides as Biomarkers of Subconcussion and Concussion.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Modeling biomarker kinetics of Aβ levels in serum following blast.Frontiers in neurology · 2025
   Article
2. Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury.Diagnostics (Basel, Switzerland) · 2023
   Review
3. Mathematical model of mechanobiology of acute and repeated synaptic injury and systemic biomarker kinetics.Frontiers in cellular neuroscience · 2023
   Article
4. Serum Amyloid Beta Precursor Protein, Neurofilament Light, and Visinin-like Protein-1 in Rugby Players: An Exploratory Study.Sports (Basel, Switzerland) · 2022
   Article
5. Updated Review of Neurologic Concussion Biomarkers for Time-sensitive Point-of-care Testing.Journal of emergencies, trauma, and shock
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as